title: FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
authors.affiliation: Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993-0002, USA. Virginia.Kwitkowski@fda.hhs.gov
authors.forename: Virginia E
authors.initials: VE
authors.lastname: Kwitkowski
authors.forename: Tatiana M
authors.initials: TM
authors.lastname: Prowell
authors.forename: Amna
authors.initials: A
authors.lastname: Ibrahim
authors.forename: Ann T
authors.initials: AT
authors.lastname: Farrell
authors.forename: Robert
authors.initials: R
authors.lastname: Justice
authors.forename: Shan Sun
authors.initials: SS
authors.lastname: Mitchell
authors.forename: Rajeshwari
authors.initials: R
authors.lastname: Sridhara
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur